Focus Gold Corp (FGLD) 0.0001 $FGLD
California Gold
Focus Gold Corp (FGLD) 0.0001 $FGLD
California Gold Issues Correction to Its Press Release Issued May 30, 2016
Filing Services Canada XHTML - Wed Jun 01, 12:23PM CDT
CGM.VN: 0.630 (-0.020)
California Gold Intersects 8.2 M Of 4.43 G/T and 11.4 M of 2.70 G/T at its Fremont Gold Project**
Filing Services Canada - Mon May 30, 8:53AM CDT
California Gold Intersects 8.2 M Of 4.43 G/T and 11.4 M of 2.70 G/T at its Fremont Gold Project**
CGM.VN: 0.630 (-0.020)
California Gold Intersects 4.9 M Of 6.91 G/T, Including 0.7 M Of 43.03 G/T, And 8.4 M Of 3.58 G/T At Its Fremont Gold Project**
Filing Services Canada XHTML - Mon May 09, 11:04AM CDT
CGM.VN: 0.630 (-0.020)
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...
Continue Reading
Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...
Continue Reading
Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...
Continue Reading
Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...
Continue Reading
Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...
Continue Reading